Investor Relations

Investor Relations

Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH).

Stock Quote

Price

Change

High

$

Copyright Nasdaq. Minimum 15 minutes delayed.

Copyright Nasdaq. Minimum 15 minutes delayed.